MedsEngine has filed a notice of an exempt offering of securities to raise $5,795,454.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, MedsEngine is raising up to $5,795,454.00 in new funding. Sources indicate that as part of senior management President, Michael Gearhardt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About MedsEngine
MedsEngine is an EHR-integrated clinical decision support application that generates real-time, personalized, evidence-based medical therapy recommendations for chronic diseases: Hypertension, Cholesterol, Type 2 Diabetes, Heart Failure. MedsEngine combines optimized medication recommendations with actionable patient engagement tools to increase medication precision and adherence. Doctors achieve nation-leading control rates, increased HEDIS scores, lower costs, and greater patient satisfaction.
To learn more about MedsEngine, visit http://www.medsengine.com/
Contact:
Michael Gearhardt, President
937-341-6738
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.